無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国のモンテルカスト市場の分析

Investigation Report on China's Montelukast Market, 2018-2022

発行 China Research and Intelligence 商品コード 296860
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.61円で換算しております。
Back to Top
中国のモンテルカスト市場の分析 Investigation Report on China's Montelukast Market, 2018-2022
出版日: 2018年11月29日 ページ情報: 英文 30 Pages
概要

中国国内には現在、ぜんそく患者が3000万人、アレルギー性鼻炎患者が3000〜4000万人存在しており、また環境汚染の悪化と共に患者数はさらに増加するものと思われます。モンテルカスト(montelukast)は最適な抗ぜんそく薬の一つとして考えられています。2005年の上市から2010年にかけて、同国のモンテルカスト市場は年平均(CAGR)45%もの速度で急成長してきました。競合企業が参入して以降は成長率は低下しましたが、それでも年間10%の成長率を維持しており、巨大な潜在的市場を抱えています。

当レポートでは、中国におけるモンテルカスト市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果をお届けします。

第1章 モンテルカストの関連概念

  • 定義
  • 症状
  • 世界市場での販売状況

第2章 中国のモンテルカスト市場の概要

  • 特許の現状
  • 主要メーカー
  • 市場規模

第3章 モンテルカストの売上高の分析

  • 売上高
  • 販売量

第4章 主要メーカーの市場シェアの分析

  • 市場シェア(金額ベース)
  • 市場シェア(数量ベース)

第5章 剤形別の市場規模の分析

  • 剤形別の市場シェア(金額ベース)
  • 剤形別の市場シェア(数量ベース)

第6章 モンテルカストの病院向け基準価格(企業別)

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)
  • Merck Shark. Dohme, MSD(UK)

第7章 主要メーカーの分析

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)

第8章 中国のモンテルカスト市場の将来展望

  • 市場規模の予測
  • 市場競争の予測

図表一覧

目次
Product Code: 1811351

Description

More than 300 million people in the world are suffering from seasonal asthma of varying degrees. The number is higher in countries with severe environmental pollution and high tobacco consumption. Asthma and allergic rhinitis are common nowadays. Owing to heavy air pollution, the incidences of these diseases are increasing year by year.

Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed. In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of "Singulair". In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.

In 1999, MSD's Montelukast chewable tablets (5mg) and tablets (10mg) were approved to enter China in the trade name of "Singulair", followed by Montelukast chewable tablets (4mg) and granules (4mg). In 2006, the generic Montelukast tablets (10mg) and chewable tablets (5mg) by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to be sold in the trade name of "Bystine". Many other companies in China have also filed applications for generic Montelukast.

According to CRI's market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.

According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.

Topics Covered:

  • Situation of respiratory diseases in China
  • Supply and sales of Montelukast in China
  • Prices of Montelukast in China
  • Competition on China's Montelukast market
  • Market share of Montelukast manufacturers in China
  • Prospect of China's Montelukast Market, 2018-2022

Table of Contents

Table of Contents

1 Basic Concept of Montelukast

  • 1.1 Indications for Montelukast
  • 1.2 Development of Montelukast in China
  • 1.3 Government Approval of Montelukast in China

2 Sales of Montelukast in China, 2013-2017

  • 2.1 Sales Value of Montelukast
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Montelukast
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Montelukast by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Granules

3 Analysis on Major Montelukast Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Montelukast Manufacturers 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 MSD
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of MSD's Montelukast in China
  • 3.3 Lunan Better Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast in China
  • 3.4 Sichuan Otsuka Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast in China

4 Prices of Montelukast in China, 2017-2018

  • 4.1 MSD (Singulair)
  • 4.2 Lunan Better Pharmaceutical Co., Ltd. (Pingqi)
  • 4.3 Sichuan Otsuka Pharmaceutical Co., Ltd. (Bystine)

5 Prospect of China's Montelukast Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Governmental Approval of Montelukast in China
  • Chart Sales Value of Montelukast in China, 2013-2017
  • Chart Sales Value of Montelukast in Parts of China, 2013-2017
  • Chart Sales Volume of Montelukast in China, 2013-2017
  • Chart Sales Volume of Montelukast in Parts of China, 2013-2017
  • Chart Sales Value of Montelukast Tablets in China, 2013-2017
  • Chart Sales Value of Montelukast Granules in China, 2013-2017
  • Chart Market Share by Sales Value of Top 3 Montelukast Manufacturers, 2013-2017
  • Chart Market Share by Sales Volume of Top 3 Montelukast Manufacturers, 2013-2017
  • Chart Sales Value of MSD's Montelukast, 2013-2017
  • Chart Sales Volume of MSD's Montelukast, 2013-2017
  • Chart Sales Value of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Volume of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Value of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Volume of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Prices of MSD's Montelukast in Parts of China, 2017-2018
  • Chart Prices of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast in Parts of China, 2017-2018
  • Chart Prices of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast in Parts of China, 2017-2018
  • Chart Forecast on Sales Volume of Montelukast in China, 2018-2022
Back to Top